We have a mechanistically and structurally diverse portfolio of small molecules which have the potential to be first in class with multiple applicability across some of the most common types of cancer.

Programme Discovery Lead Optimisation Preclinical Development Phase 1 Clinical Development
Phortress - CYP-activated , DNA-interactive agent (breast, ovarian, renal, lung) Phortress Graph
PMX 500 - Telomere targeting agents (broad spectrum activity) PMX 500 Graph
PMX 700 - repair resistant DNA-interactive agents (broad spectrum activity) PMX 700 Graph
PMX 900 - Base Excision Repair inhibitors, undisclosed target (broad spectrum activity) PMX 900 Graph
  • Print this page
  • Email this page to a friend